Early Diagnosis leads to better Patient Outcomes | Endosure
As we enter the third day of Endometriosis Awareness Month, it's crucial that we keep the spotlight on this condition and its impact on the lives of millions of women around the world. By helping raise awareness, we hope that increased funding for research will be made available, allowing us to move closer to providing relief for 190 million women who suffer from this debilitating disease.
At ENDOSURE, INC. we are committed to this cause, Doctors tell us that our revolutionary test can play a significant role in early diagnosis of endometriosis in a cost effective manner. By doing so, they can discover the disease at earlier stages, thereby providing early treatment options to help minimize disease progression and improve the lives of millions of women.
This week, we are excited to announce that the EndoSure family has grown with the addition of new distributors on both sides of the Atlantic, reflecting the global scale of this problem. We are delighted to announce we will be at the upcoming World Congress on Endometriosis (WCE), to be held in Edinburgh from 3 to 6 May of 2023.
We believe that our presence at this important event will be an opportunity to showcase the EndoSure Test, and to connect with others who share our passion for improving the lives of women with endometriosis. We are pleased to - offer a diagnostic option for this community, and to continue to push for progress in the fight against endometriosis.
But by working together, raising awareness, and introducing this innovative diagnostic test, we can make a real difference.
This Endometriosis Awareness Month, let's keep the conversation going and keep fighting for a brighter future for women with endometriosis.
... it's about time.
About Us
EndoSure offers the only non-invasive, 30-minute test to support the diagnosis of endometriosis that not only fills the gap, but addresses the vacuum in this area of women’s health care.*
© July 2024 ENDOSURE, Inc. All rights reserved
1. Approximately 15-20 minutes of patient preparation time may be required prior to performing the test.
2. Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8.
3. i. Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024 May 13;13(10):2866. doi: 10.3390/jcm13102866. PMID: 38792407; PMCID: PMC11122642.
4. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Viganò, P. Endometriosis. Nat. Rev. Dis. Primers. 2018:4-9.
5. 1. Noar M, Mathias J, Kolatkar A. Validation of New GIMA Biomarker Signature of Endometriosis - Interim Data: Research Article. TechRxiv. August 26, 2024. DOI: 10.22541/au.172469630.08159498/v1
6. 1. Kitsantas P, Benson KN, Al-Farauki S, Knecht MK, Hennekens CH, et al. (2024) Emerging Diagnostic Tools for the Early Diagnosis of Endometriosis. J Reprod Med Gynecol Obstet 9: 171.
DISCLAIMER: THE ENDOSURE TEST IS A CLINICAL DECISION SUPPORT TOOL INTENDED TO INFORM AND ENHANCE A HEALTHCARE PROVIDER'S DECISION-MAKING PROCESS, WHICH MUST BE INDIVIDUALIZED FOR EACH PATIENT'S CIRCUMSTANCES AND TAKE INTO ACCOUNT THE FULL SCOPE OF MEDICAL DATA AND INFORMATION AVAILABLE TO THE PROVIDER. THE ENDOSURE TEST IS NOT INTENDED TO SUBSTITUTE, REPLACE, OVERRULE, OR DIRECT A HEALTHCARE PROVIDER’S JUDGMENT.
* US CUSTOMERS: Endosure is currently available for research use only and not clinical use.